OAKLAND, Calif.--(EON: Enhanced Online News)--Riffyn, a provider of visual design and data analytics software, announces the formation of a multiyear partnership with Novozymes to deploy and develop Riffyn’s ground-breaking cloud-based software for experiment design and data analytics. Riffyn’s Software-as-a-Service (SaaS) will be implemented progressively across Novozymes’ 1000-person global R&D organization to help support accelerated product development.
“Novozymes is one of the most innovative industrial biotechnology companies in the world. We are excited to help them achieve unprecedented efficiency and effectiveness in their product development”
“Riffyn delivers a vehicle to harvest data from our global lab processes in a structured yet flexible way. By means of Riffyn’s process oriented data model, we will be able to even further strengthen our lab flows,” said Søren Egestad, Director of Scientific Data Management and Analysis at Novozymes. “Riffyn helps us to secure a close connection between the lab process and the data collected and stored for analysis. In our perspective, Riffyn offers a new and differentiating paradigm for the lab side of our scientific data management activities.”
“Novozymes is one of the most innovative industrial biotechnology companies in the world. We are excited to help them achieve unprecedented efficiency and effectiveness in their product development,” said Timothy Gardner, Founder and CEO of Riffyn. “The deep partnership with Novozymes is also a great boost to Riffyn’s own product development—helping us to rapidly expand our data acquisition and visualization capabilities.”
Novozymes selected Riffyn as a partner in its global research strategy to address their exponentially growing R&D data. The company sought solutions that could provide real-time access to high-quality structured data sets—allowing them to be linked, blended, analysed and visualized across technical teams, while continuously adapting to constantly evolving R&D processes. Riffyn SaaS, which offered differentiating capabilities to address these needs, fits well into Novozymes research’s evolving big data strategy.
The challenges experienced by Novozymes are reflective of broader data issues that have emerged in scientific R&D due to the explosion of experimental data and complexity. As widely recognized in recent years, these problems have resulted in low experimental data quality and barriers to effective collaboration. By Riffyn’s analysis these issues collectively cost global R&D organizations well over $100B per year in wasted research effort and delayed technology commercialization.
Riffyn is a provider of research design and analytics software (SaaS) to biotech, pharmaceutical, food and chemical industries. Riffyn SaaS offers a unique “design-first” approach to scientific experimentation and product development that solves previously intractable data fragmentation issues. Riffyn’s SaaS provides global R&D organizations with unprecedented access to high-quality data, process design information and integrative data analytics. The company was founded in 2014 by veterans from the life science and high-performance computing industries, and is headquartered in Oakland, California. Learn more at www.riffyn.com.
Novozymes is the world leader in biological solutions. Together with customers, partners and the global community, Novozymes improves industrial performance while preserving the planet’s resources and helping build better lives. As the world’s largest provider of enzyme and microbial technologies, Novozymes’ bioinnovation enables higher agricultural yields, low-temperature washing, energy-efficient production, renewable fuel and many other benefits that society relies on today and in the future. Learn more at www.novozymes.com
Reference links on R&D data, collaboration and tech transfer challenges